XM levert geen diensten aan inwoners van de Verenigde Staten.
B
B

Biomarin


Nieuws

BridgeBio climbs on positive mid-stage trial for genetic condition treatment

BUZZ-BridgeBio climbs on positive mid-stage trial for genetic condition treatment ** Shares of drug developer BridgeBio Pharma BBIO.O rise ~8% to $31.29 premarket ** Co says its oral therapy infigratinib showed significant improvement in body proportionality in patients with achondroplasia, during a mid-stage trial ** Achondroplasia is a genetic bo
B

U.S. Bath & Body Works, Under Armour, Viking Therapeutics

U.S. RESEARCH ROUNDUP-Bath & Body Works, Under Armour, Viking Therapeutics May 17 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Bath & Body Works, Under Armour and Viking Therapeutics, on Friday. HIGHLIGHTS * Advanced Drainage Systems Inc WMS.N : Barclays raises target price to $202 from $189 * Bath & Body Works Inc BBWI.N : JP Morgan raises to neutral from underweight * Tanger Inc SKT.N : Scotiabank raises to sect
B
C
G
M
T
A
A
C
D
T

Third Point Llc Takes Share Stake In Alphabet, Advance Auto Parts; Dissolves In U.S. Steel, Dupont

BRIEF-Third Point Llc Takes Share Stake In Alphabet, Advance Auto Parts; Dissolves In U.S. Steel, Dupont May 15 (Reuters) - Third Point LLC: THIRD POINT LLC TAKES SHARE STAKE OF 3.0 MILLION SHARES OF CLASS A CAPITAL STOCK - SEC FILING THIRD POINT LLC TAKES SHARE STAKE OF 1.5 MILLION SHARES IN ADVANCE AUTO PARTS INC THIRD POINT LLC DISSOLVES SHARE S
B
G
U
M
A

U.S. Akoya Biosciences, Boston Beer Company, Victory Capital Holdings

U.S. RESEARCH ROUNDUP- Akoya Biosciences, Boston Beer Company, Victory Capital Holdings May 14 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Akoya Biosciences, Boston Beer Company and Victory Capital Holdings on Tuesday. HIGHLIGHTS * Akoya Biosciences Inc AKYA.O : Canaccord Genuity cuts target price to $6 from $10 * Boston Beer Company Inc SAM.N : Jefferies raises target price to $360 from $335 * Fortrea Holdings I
B
C
A
A
C

Biomarin's Says New Data For Vosoritide Presented At Pediatric Endocrine Society (PES) Annual Meeting

BRIEF-Biomarin's Says New Data For Vosoritide Presented At Pediatric Endocrine Society (PES) Annual Meeting May 4 (Reuters) - Biomarin Pharmaceutical Inc BMRN.O : NEW DATA FOR BIOMARIN'S VOXZOGO® (VOSORITIDE) FOR MULTIPLE GROWTH-RELATED CONDITIONS IN CHILDREN PRESENTED AT PEDIATRIC ENDOCRINE SOCIETY (PES) ANNUAL MEETING Source text for Eikon: ID:n
B

U.S. STOCKS Loar, Regeneron, Intel

BUZZ-U.S. STOCKS ON THE MOVE-Loar, Regeneron, Intel Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 U.S. stocks slumped on Thursday as most megacaps fell after Meta Platforms' quarterly results, while sentiment was shaken amid signs of persistent inflation that dampened hopes of the Federal Reserve easing monetary policy anytime soon.
A
B
B
B
C
C
G
I
M
N
N
P
R
T
L
T
U
U
D
R
S
T
W
C
D
L
T

U.S. STOCKS Viking, Alphabet, Dover

BUZZ-U.S. STOCKS ON THE MOVE-Viking, Alphabet, Dover Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 U.S. stocks were sharply lower on Thursday, dragged down by growth stocks after dour quarterly results from Meta Platforms, while signs of persistent inflation dampened hopes of the Federal Reserve cutting interest rates anytime soon.
A
B
B
B
C
G
M
M
N
N
R
T
L
U
U
D
R
S
T
W
C
D
T

BioMarin falls after Q1 revenue miss

BUZZ-BioMarin falls after Q1 revenue miss ** Shares of drugmaker BioMarin Pharmaceutical BMRN.O falls ~10.8% to $81.35 ** Co reported Q1 revenue of $648.80 mln after market close on Wednesday, missing analysts' average expectation of $651.80 mln - LSEG data ** BMRN posts quarterly adj. profit of 71 cents/shr vs analysts' average estimates of 34 cen
B

U.S. Doximity, Monster Beverage, ServiceNow

U.S. RESEARCH ROUNDUP- Doximity, Monster Beverage, ServiceNow April 25 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Doximity, Monster Beverage and ServiceNow, on Thursday. HIGHLIGHTS * Doximity Inc DOCS.N : JP Morgan raises to neutral from underweight * Monster Beverage Corp MNST.O : JP Morgan cuts to neutral from overweight * ServiceNow Inc NOW.N : HSBC raises target price to $905 from $874 * Trustmark Corp TRMK.
A
A
A
B
B
B
C
C
H
M
L
S
A
A
C

Biomarin Pharmaceutical Inc reports results for the quarter ended in March - Earnings Summary

Biomarin Pharmaceutical Inc reports results for the quarter ended in March - Earnings Summary Biomarin Pharmaceutical Inc BMRN.OQ reported quarterly adjusted earnings of 46 cents​​ per share for the quarter ended in March, higher than the same quarter last year, when the company reported EPS of 27 cents. The mean expectation of twenty three analysts for the quarter was for earnings of 35 cents per share.
B

Biomarin Pharmaceutical Q1 EPS USD 0.46

BRIEF-Biomarin Pharmaceutical Q1 EPS USD 0.46 Apr 24 (Reuters) - Biomarin Pharmaceutical Q1 revenue USD 648.8 million vs. IBES estimate USD 651.8 million. Q1 adjusted EPS USD 0.71 vs. IBES estimate USD 0.34 Q1 basic EPS USD 0.47 Q1 net income USD 88.7 million vs. IBES estimate USD 62.6 million
B

Biomarin Pharmaceutical Inc <BMRN.OQ> expected to post earnings of 35 cents a share - Earnings Preview

Biomarin Pharmaceutical Inc expected to post earnings of 35 cents a share - Earnings Preview Biomarin Pharmaceutical Inc BMRN.OQ BMRN.O is expected to show a rise in quarterly revenue when it reports results on April 24 for the period ending March 31 2024 The Novato California-based company is expected to report a 9.3% increase in revenue to $651.788 million from $596.42 million a year ago, according to the mean estimate from 22 analysts, based on LSEG data.
B

U.S. American Express, Philip Morris, Royal Gold

U.S. RESEARCH ROUNDUP-American Express, Philip Morris, Royal Gold April 22 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including American Express, Philip Morris and Royal Gold, on Monday. HIGHLIGHTS * American Express Co AXP.N : TD Cowen raises target price to $225 from $221 * Philip Morris PM.N : Jefferies raises target price to $101 from $98 * PPG Industries Inc PPG.N : Evercore ISI cuts to in line from outperform * Roya
A
A
A
A
B
B
C
C
D
E
H
I
L
F
U
A
A
C



Voorwaarden

Populaire activa

Disclaimer: De entiteiten van de XM Group bieden diensten en toegang tot ons online handelsplatform op basis van uitsluitend-uitvoering, waardoor een persoon de beschikbare content op of via de website kan bekijken en/of gebruiken, zonder dat dit is bedoeld voor wijziging of uitbreiding. Dergelijk(e) toegang en gebruik vallen onder: (i) de algemene voorwaarden; (ii) risicowaarschuwingen; en de (iii) volledige disclaimer. Dergelijke content wordt daarom alleen aangeboden als algemene informatie. Wees u er daarnaast vooral van bewust dat de inhoud op ons online handelsplatform geen verzoek of aanbieding omvat om transacties op de financiële markten uit te voeren. Het beleggen op welke financiële markt dan ook vormt een aanzienlijk risico voor uw vermogen.

Alle materialen die op ons online handelsplatform worden gepubliceerd zijn bedoeld voor educatieve/informatieve doeleinden en omvatten geen – en moeten niet worden beschouwd als het bevatten van – financieel, vermogensbelastings- of handelsadvies en aanbevelingen, of een overzicht van onze handelsprijzen, of een aanbod of aanvraag van een transactie in financiële instrumenten of ongevraagde financiële promoties voor u.

Alle content van derden, alsmede content die is voorbereid door XM, zoals opinies, nieuws, onderzoeken, analyses, prijzen en andere informatie of koppelingen naar externe websites op deze website worden aangeboden op een 'zoals-ze-zijn'-basis, als algemene marktcommentaren, en vormen geen beleggingsadvies. Voor zover dat content wordt beschouwd als beleggingsonderzoek, moet u zich ervan bewust zijn en accepteren dat de content niet bedoeld was en niet is voorbereid in overeenstemming met de wettelijke vereisten die zijn opgesteld om de onafhankelijkheid van beleggingsonderzoek te bevorderen en als zodanig onder de geldende wetgeving en richtlijnen moet worden beschouwd als marketingcommunicatie. Zorg ervoor dat u onze Mededeling over niet-onafhankelijk beleggingsonderzoek en risicowaarschuwing in verband met de voorgaande informatie doorneemt en begrijpt; die kunt u hier lezen.

Risicowaarschuwing: Uw vermogen loopt risico. Hefboomproducten zijn mogelijk niet voor iedereen geschikt. Lees onze informatie over risico's.